Heart Failure Pharmacology Flashcards
What are the stages of heart failure
What are the staples of HF therapy
Diuretics + salt/fluid restriction AND
ACE/ARB + BB
What are ARNIs and effect
Angiotensin Receptor Blocker/Neprilysin Inhibitor
More Natriuretic Peptide effect (more vasodilat), Less AT1 effect (less vasoconstriction)
Eligibility for ARNI
–EF <35%, NYHA II-III
–GFR >30, K <5.0
–SBP >95mmHg
–On stable dose of ACE-I/ARB
- BEWARE hypotension
- Do NOT use if h/o angioedema
Aldosterone antagonists and side effects
•Spironolactone: Old drug, cheap
–Adverse Effects: Hyperkalemia* (increase in deaths seen after widespread use), 10% gynecomastia
•Eplerenone: New drug, expensive, less gynecomastia
–Adverse Effects: Hyperkalemia
BB shown to have mortality benefit in HFrEF, what is the benefit
Metoprolol XL (succinate), Carvedilol, Bisoprolol (Europe)
The beneft of BB is primarly CHRONIC – reduce arrhythmia, protect from adverse effects of chronic adrenergic stimulation, lead to reverse remodeling
Adverse effects of beta blockers
Adverse Effects: Hypotension, bradycardia, depression, erectile dysfunction, AV block, bronchospasm (rarely)
CAUTION with dosing in acute decompensated heart failure – the abrupt negative inotropic effects of BB can worsen the decompensation
Effects of ISDN/Hydralazine and adverse effects
Vasodilator therapy, causes afterload reduction
Mortality benefit in Black pts who are optimized on BB/ACE-I (A-HeFT study)
Adverse Effects: Headache, dizziness, hypotension
Broad treatment for patient profile. (4 states)
Warm and Wet treatment
Diuretics + Afterload Reduction
Diuretics used for HF
Loop diuretics are staple – use IV at least BID
Thiazide diuretics are add-on therapy if loop diuretics reaching high doses without significant effect (Metalazone)
What is the significance of JVP
- Surrogate measurement for intravascular volume
- Measuring central venous pressure (CVP), which is surrogate for right atrial pressure (RAP), which can be surrogate for pulmonary capillary wedge pressure (PCWP), which is a surrogate for LV end diastolic pressure (LVEDP)
Purpose of afterload reduction in HF
- Heart failure causes activation of the Renin-Angiotensin-Aldosterone system
- Decreased cardiac output à diminished renal blood flow à activation of RAAS
–ATII increases afterload (vasoconstriction) + Na/H2O retention in kidney
–Aldosterone increases Na/Fluid absorption in kidney
Approad to beta blockers with HF
Treatment stapes for cold and wet
Diuretics + Afterload Reduction + Inotropes